Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial discipline, positive operating cash flow, and strategic growth plans for RUCONEST and Joenja, including international expansion. Despite a slight revenue drop for RUCONEST, new enrollments and prescribers provide a sustainable growth outlook. The Q&A section indicates confidence in future growth, particularly in Joenja’s international markets. However, management’s lack of clarity on specific metrics could cause some investor caution. Overall, the positive growth outlook and financial discipline suggest a positive stock price movement within the 2% to 8% range over the next two weeks.
Key Financial Performance
RUCONEST Revenue Revenue was down 15% year-on-year. The decline was driven by three factors: inventory dynamics reducing revenue by 8%, planned exit from ex-U.S. markets contributing 3%, and competition from new treatment options in the U.S. HAE market. Despite this, approximately 50 new patient enrollments and 23 new prescribers were added in Q1 2026.
Joenja Revenue Revenue grew by 34% year-on-year, reaching $14.1 million globally. This growth was driven by a 25% increase in U.S. patients year-on-year, strong patient uptake in the U.K., and growth in government-supported access programs internationally. The U.S. fill rate remained high at 85%.
Total Q1 Revenue $72.4 million, down 8% year-on-year. The decline was primarily due to the 15% drop in RUCONEST revenue, partially offset by the 34% growth in Joenja revenue.
Operating Expenses Total operating expenses were down by 9% year-on-year. Adjusted for nonrecurring acquisition costs in Q1 2025, overall expenses were flat. Incremental R&D investments for napazimone amounted to $2.7 million.
Operating Cash Flow Positive operating cash flow of $2 million was generated in Q1 2026, reflecting strong cost management and financial discipline.
Cash and Marketable Securities Decreased by $9.3 million to $171.8 million, primarily due to a $12.3 million payment related to early termination of the DSP facility lease.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Joenja Revenue Growth: Joenja revenues grew by 34%, reflecting strong momentum in the U.S. with a 25% year-on-year increase in patients and international market growth. Regulatory progress positions Joenja for launches in Japan and Europe later this year, and label expansion to pediatric populations in the U.S. is underway.
RUCONEST Performance: RUCONEST revenue declined by 15% due to inventory drawdown, planned exit from non-U.S. markets, and competition from new treatments. Despite this, 50 new patients were enrolled, and 23 new prescribers were added in Q1 2026.
Geographic Expansion for Joenja: Joenja is set to launch in Japan and Europe later this year, expanding its market reach.
Pediatric Market Expansion for Joenja: Efforts are underway to expand Joenja's label to pediatric populations in the U.S., with regulatory submissions made for higher and lower doses.
Cost Management: Disciplined cost management resulted in positive operating cash flow of $2 million in Q1 2026. Operating expenses were reduced by 9% year-on-year, and a 20% G&A structural headcount reduction was implemented.
Revenue Guidance: Revenue guidance for 2026 is maintained at $405 million to $425 million, representing 8% to 13% year-on-year growth.
Focus on High-Return Markets: Pharming exited non-U.S. markets for RUCONEST to focus resources on higher-return markets.
Pipeline Development: Significant pipeline catalysts include Phase II trial readouts for leniolisib in higher prevalent PID and completion of napazimone registrational study enrollment in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline in RUCONEST: Quarterly revenue dropped due to inventory drawdown at specialty pharmacy and the planned exit from non-U.S. markets, which was part of a strategy to focus resources on higher-return areas. This decline reflects challenges in maintaining revenue stability.
Competition in HAE Market: New treatment options entering the U.S. HAE market have led to limited patient interest in switching to RUCONEST, although some patients returned after inadequate responses to alternatives. This indicates competitive pressures in the market.
Regulatory Challenges for Joenja: The FDA issued a Complete Response Letter (CRL) for Joenja's pediatric label expansion, citing clinical pharmacology and analytical batch testing issues. Although progress has been made, regulatory hurdles remain a challenge.
Supply Chain and Inventory Dynamics: Inventory normalization and timing affected revenues for both RUCONEST and Joenja, highlighting operational challenges in managing supply chain and inventory levels.
Economic and Financial Discipline: The company is undergoing cost management initiatives, including a 20% reduction in G&A headcount, to maintain financial discipline. This reflects challenges in balancing operational costs with growth investments.
Pipeline Development Risks: Significant investments in pipeline development, including napazimone and leniolisib, carry inherent risks related to clinical trial outcomes and regulatory approvals.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company maintains its revenue guidance of $405 million to $425 million for 2026, representing growth between 8% and 13% year-on-year.
Joenja Growth Projections: Joenja revenues are expected to accelerate, with annual growth over 10 percentage points higher than in 2025. The company is planning launches in Japan and Europe this year and expects U.S. pediatric label revenues later this year.
RUCONEST Revenue Expectations: RUCONEST is expected to achieve low single-digit annual growth at the midpoint of the guidance range, with some pressure on revenue in Q2 and growth in the second half of the year.
Pipeline Catalysts: The company anticipates significant pipeline catalysts later this year, including the readout of two Phase II trials for leniolisib in higher prevalent PID and the completion of enrollment for the napazimone registrational study in primary mitochondrial disease.
Operating Expenses for 2026: Operating expenses are expected to be between $330 million to $335 million, including $60 million in incremental R&D investment to advance the pipeline.
Gross Margin Expectations: Gross margin is expected to be approximately 90% for 2026.
Cash Flow and Financial Discipline: Available cash and future operating cash flows are expected to fully support all pipeline investments, including prelaunch activities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is there expected further pressure on RUCONEST sales in Q2, and what gives confidence in returning to growth in the second half of the year?
A:The company is in the early stages of competitive entry, with 9 months into the sebetralstat launch followed by prophylactic treatments. It takes 3-4 reorder cycles to see the full impact of trialing and switching behavior. Growth in the second half is expected due to the addition of new prescribers and patient enrollments, particularly among high-burden HAE patients who benefit from RUCONEST.
Q:What is the outlook for Joenja in Europe and Japan?
A:The first European launch will be in Germany towards the end of Q2, with commercial patients expected. The Japan launch is anticipated in August. These launches, along with a potential pediatric approval in the U.S., are key growth drivers for Joenja.
Q:What is the status of the inventory drawdown for RUCONEST?
A:The inventory drawdown follows the normal cycle of the year. Compared to 2025, the drawdown is more reflective of a normal cycle, with inventory build expected in the second half of the year to meet demand.
Q:How does the 4% revenue drop for RUCONEST relate to inventory drawdowns and new patient enrollments?
A:The 4% revenue drop is not associated with inventory drawdowns but rather with planned U.S. and ex-U.S. exits. The 50 new patient enrollments are expected to offset this drop, though there is a delay between enrollment and therapy initiation.
Q:What are the expectations for leniolisib Phase I/II readouts and their alignment with Phase III endpoints?
A:The Phase I/II readouts focus on immune dysregulation, including lymphoproliferation and autoimmune disease. Improvements in lymph node size, spleen size, blood counts, and other markers are being measured. These endpoints align with Phase III studies.
Q:What are the key drivers for revenue guidance and assumptions for compassionate use experience in CVID?
A:Key drivers include the timing of U.S. pediatric approval and launch, which could accelerate revenue. The compassionate use experience in CVID shows improvements in immune dysregulation among a sicker group of patients, resembling those in the Phase II study.
Q:What is the proportion of identified 4- to 11-year-old APDS patients in the U.S., and has the FDA feedback changed the pediatric dosing strategy?
A:Approximately 50% of the 4- to 11-year-old APDS population would be eligible for high-dose leniolisib. The FDA feedback has not changed the dosing strategy, as efficacy observed across doses supports maintaining the same doses in the resubmission strategy.
Q:Will the Phase II leniolisib readouts be released simultaneously, and what are the expectations for good data?
A:The readouts may not be simultaneous, as one study is shorter in duration. Good data would include improvements in lymph node and spleen size, blood counts, and other end-organ disease manifestations, aligning with previous APDS data and early expanded access results.
Q:Is the addition of 50 new RUCONEST enrollments and 23 new prescribers in Q1 sustainable, and what is the impact of Ekterly on patient retention?
A:The addition of new enrollments and prescribers is seen as sustainable due to RUCONEST's differentiated profile. The launch of Ekterly has made the on-demand market more dynamic, but only a small percentage of RUCONEST patients have tried Ekterly, with limited adoption.
Q:What is the growth outlook for Joenja in the U.S. and internationally?
A:Joenja has significant growth potential in the 12 and above U.S. population, with sustainable momentum into Q2. Pediatric approval in the second half and international launches in Germany and Japan are additional growth drivers.
Q:What additional work is required for the low-dose leniolisib resubmission, and why was a two-submission approach chosen?
A:The low-dose resubmission requires compiling efficacy data that aligns with high-dose results. The two-submission approach was chosen to expedite approval for the high-dose group while leveraging existing data for the low-dose group.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantification on the percentage of RUCONEST patients trying Ekterly and their return rate. Additionally, they did not provide exact timing for the Phase II leniolisib readouts or detailed metrics for what constitutes 'good data' in these studies.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CRL
CVID
FDA
Fabrice
HAE
Japan Europe
Joenja
Leverne
PIDs
Pharming
RUCONEST
United States
cash flow
child
decline
deficiency
disease
dos
dysregulation
exit market
expansion
inventory
investment
label
launch
leniolisib
lever
life cycle
milestone
momentum
napazimone
patient therapy
payment
resubmission
revenue
role
sNDA
signal
study
PHAR Transcript
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call reveals strong financial discipline, positive operating cash flow, and strategic growth plans for RUCONEST and Joenja, including international expansion. Despite a slight revenue drop for RUCONEST, new enrollments and prescribers provide a sustainable growth outlook. The Q&A section indicates confidence in future growth, particularly in Joenja’s international markets. However, management’s lack of clarity on specific metrics could cause some investor caution. Overall, the positive growth outlook and financial discipline suggest a positive stock price movement within the 2% to 8% range over the next two weeks.
Pharming Group N.V. (PHAR) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call presents a positive outlook with raised revenue guidance, geographic expansion, and strong pipeline development. The Q&A section reveals optimism about Joenja's growth in the U.S. and international markets, despite some uncertainties in patient conversion rates. Financial discipline and a focus on value-accretive transactions further enhance the positive sentiment. The optimistic guidance and strategic focus on expanding Joenja's market presence are likely to drive a positive stock price movement over the next two weeks.
Canfor Corporation (CFP:CA) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call indicates significant challenges, particularly in Europe with EBITDA losses and high log costs. The Q&A highlights these issues, with management expecting improvements only by 2026. The company's financial health shows net debt and liquidity, but the uncertain path for Canfor Pulp and vague management responses on strategy further contribute to a negative outlook. While North American operations show some resilience, the overall sentiment leans negative due to European struggles and lack of clear strategic direction.
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals strong financial performance with a 32% revenue increase and improved margins, alongside optimistic guidance and a raised revenue forecast. Product developments, particularly Joenja's expansion, are promising. While some uncertainties exist, such as RUCONEST's withdrawal impact, the overall sentiment remains positive due to the strong growth trajectory and strategic direction.
PHAR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
